Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IMNM
Strong SellSinkerImmunome, Inc. · Healthcare · United States · $3.1B · Avg Vol: $28M/d
COMPANY DESCRIPTION
Immunome, Inc. is a biotechnology company dedicated to developing first-in-class targeted oncology therapies, including antibody-drug conjugates (ADCs) and radiopharmaceuticals. The company's competitive moat is driven by its proprietary discovery engine, which identifies novel antibody-target pairs directly from patients who have successfully fought off disease. It operates as an innovative platform-based biotech with strategic collaborations in the high-growth oncology sector.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 14.0M | 9.0M | 6.9M | -29.6% | — | 0.3M | 55.6M | 182.9% |
| EPS | -0.33 | -2.05 | -5.00 | -2.43 | — | -2.53 | -2.31 | -2.48 | — |
| Shares | 113.3M | 113.3M | 64.5M | 113.1M | -0.1% | 113.6M | — | — | — |
| Debt | 0.3M | 1.6M | 4.8M | 3.9M | 136.6% | 4.7M | — | — | — |
| Equity | 16.7M | 119.9M | 181.2M | 634.3M | 236.5% | — | — | — | — |
| Op CF | -28.7M | -7.6M | -110.8M | -190.9M | — | -208.8M | — | — | — |
| Inv CF | -0.2M | -30.5M | -85.1M | 60.8M | — | — | — | — | — |
| Fin CF | 32.0K | 116.4M | 240.5M | 640.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IMNM are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IMNM | Immunome, Inc.(you) | $3.1B | 20 | Strong Sell |
| IRON | Disc Medicine, Inc. | $3.1B | 22 | Sell |
| DNLI | Denali Therapeutics Inc. | $3.8B | 21 | Sell |
| IDYA | IDEAYA Biosciences, Inc. | $3.9B | 21 | Sell |
| VKTX | Viking Therapeutics, Inc. | $3.8B | 18 | Strong Sell |
| CLDX | Celldex Therapeutics, Inc. | $3.1B | 25 | Sell |
| MRVI | Maravai LifeSciences Holdings, Inc. | $2.8B | 24 | Sell |
| ATAI | AtaiBeckley Inc. | $2.7B | 23 | Sell |
| RAPP | Rapport Therapeutics, Inc. | $2.3B | 19 | Strong Sell |
| MANE | Veradermics, Incorporated | $4.1B | 22 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%